NanoMedSyn develops a new platform to create innovative therapies by the addition of patented AMFA vectors to existing drugs, like therapeutic antibodies for various immunotherapies or enzymes for enzyme replacement therapy. These vectors will create a new class of therapeutics for patients suffering of lysosomal storage disorders, cancers, inflammatory or immune diseases.
NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA.
is the engineering of recombinant proteins like antibodies or enzymes for better therapies.
NanoMedSyn develops engineered therapeutics in-house and in partnership.